David FabrizioVice President, Translational Strategy at Foundation Medicine
David Fabrizio serves as the Vice President of Translational Strategy at Foundation Medicine in Cambridge, MA. Under David’s leadership, Foundation Medicine has pioneered new genomic biomarkers for immunotherapy, including tumor mutational burden (TMB), and launched the first comprehensive genomic profiling test approved by the FDA, FoundationOne CDx. David also led the development of the first blood-based assay to determine immunotherapy response, published in Nature Medicine, which was also selected as one of Nature’s most notable advances of 2018. David completed his scientific training at the University of Vermont and subsequently studied in the lab of Dr. Lin at Harvard Medical School. He holds nine different patents or patent applications for therapeutic and diagnostic methods for cancer, as well as over 25 publications in peer reviewed journals including Nature, Cell, and the Journal of American Medical Association (JAMA), and is a member of ASCO and AACR.